OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy
暂无分享,去创建一个
S. Barry | Michael Thomas | N. Rizvi | Z. Szucs | B. Besse | F. Huemer | P. Forde | K. Sachsenmeier | M. Hochmair | G. Goss | M. Awad | K. Park | R. Hobson | J. Bennouna | M. Dressman | H. Ambrose | E. Dean | J. Cosaert | P. Mortimer | J. Heymach | C. Hayward